Clinical Study
Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial
Figure 2
End-of-trial changes in HbA1c (%) in the diacerein and placebo groups, stratified by duration of diabetes < 14 (a) or ≥14 years (b), independently of age and gender.
| (a) |
| (b) |